Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2005

View Archived Issues

NB-001 successfully completes phase II study in herpes labialis

CRADA for antiviral testing of Tarvacin

SC-236 attenuates colon tumor activity associated with cigarette smoking

First dual modulator of PGI2 and TXA2 shows promise as an antithrombotic agent

New class of intestinal Pi absorption inhibitor

Japanese Committee for Usage of Unapproved Drugs rules on Chugai drugs

Nonapprovable letter for Namenda for mild Alzheimer's disease

Vernalis completes acquisition of Ionix

Acambis' C. difficile vaccine begins phase I study

Phase III study of MyVax Personalized Immunotherapy cleared to continue

Tapestry to focus on development of TPI-287

U.K. phase I study of Reolysin begins enrollment

Ozarelix begins U.S. phase I/II trial for hormone-dependent prostate cancer

Adacel vaccine now available in U.S.

Novacea and Pierre Fabre partner on oral vinorelbine

Recent patents cover novel treatments for cognitive disorders

Trifunctional bispecific antibodies show promise in the treatment of cancer

Zegerid Chewable Tablets NDA accepted for filing

Blockade of melanocortin-4 receptors increases the potency of morphine

Novel anti-HIV agents reported by Panacos

NDA for indiplon tablets accepted for review

(-)-Gossypol induces apoptosis in cisplatin-resistant head and neck cancer cells

Salagen approved in Japan

Ruboxistaurin reduces vision loss risk in patients with diabetic retinopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.